Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Zanchi

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Swiss Medical Weekly|February 29, 2016
Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugsFaiza Lamine, Fabrice Lalubin, Nelly Pitteloud, et al.
Revue Medicale Suisse|June 23, 2021
Chantal Arditi, Heike Labud, Lucien Roulet, et al.
Advances in Therapy|May 27, 2018
Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study ProtocolMarie-Eve Muller, Menno Pruijm, Olivier Bonny, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 22, 2007
Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing propertiesAnne Zanchi, Abdul G Dulloo, Christine Perregaux, et al.
American Journal of Physiology. Endocrinology and Metabolism|July 13, 2006
The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant ratsAnne Zanchi, Christine Perregaux, Marc Maillard, et al.
Swiss Medical Weekly|July 12, 2017
Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practicesAntonella Corcillo, Edward Pivin, Fabrice Lalubin, et al.
Revue Medicale Suisse|June 1, 2023
[Diabetic nephropathy: Interprofessional support of medication adherence]Carole Bandiera, Dina Duarte, Jennifer Dotta-Celio, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2004
Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy menAnne Zanchi, Arnaud Chiolero, Marc Maillard, et al.
Revue Medicale Suisse|June 11, 2020
[Post-transplantation diabetes in kidney transplant: from the diabetologist point of view]Amélie Pauchet, Nora Schwotzer, Faiza Lamine, et al.
Metabolism: Clinical and Experimental|October 2, 2009
Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gainGregory Aubert, Michel Burnier, Abdul Dulloo, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Swiss Medical Weekly|February 29, 2016
Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugsFaiza Lamine, Fabrice Lalubin, Nelly Pitteloud, et al.
Revue Medicale Suisse|June 23, 2021
Chantal Arditi, Heike Labud, Lucien Roulet, et al.
Advances in Therapy|May 27, 2018
Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study ProtocolMarie-Eve Muller, Menno Pruijm, Olivier Bonny, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 22, 2007
Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing propertiesAnne Zanchi, Abdul G Dulloo, Christine Perregaux, et al.
American Journal of Physiology. Endocrinology and Metabolism|July 13, 2006
The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant ratsAnne Zanchi, Christine Perregaux, Marc Maillard, et al.
Swiss Medical Weekly|July 12, 2017
Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practicesAntonella Corcillo, Edward Pivin, Fabrice Lalubin, et al.
Revue Medicale Suisse|June 1, 2023
[Diabetic nephropathy: Interprofessional support of medication adherence]Carole Bandiera, Dina Duarte, Jennifer Dotta-Celio, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2004
Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy menAnne Zanchi, Arnaud Chiolero, Marc Maillard, et al.
Revue Medicale Suisse|June 11, 2020
[Post-transplantation diabetes in kidney transplant: from the diabetologist point of view]Amélie Pauchet, Nora Schwotzer, Faiza Lamine, et al.
Metabolism: Clinical and Experimental|October 2, 2009
Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gainGregory Aubert, Michel Burnier, Abdul Dulloo, et al.
Pageof 5